ClinicalTrials.gg
TerminatedNCT01853228Updated Jun 17, 2019Results posted

A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia

A Phase 1/2 interventional study of Phase1 and Phase 2: decitabine and Phase 1: cytarabine in Acute Myeloid Leukemia, sponsored by Janssen Research & Development, LLC. Terminated at 17 sites in 7 countries. Open to participants aged 1 Month to 18 Years. Per ClinicalTrials.gov, last updated 2019-06-17.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1/2, Interventional, and Treatment

Why this study was terminated
EMA/PDCO acknowledged that available results from this study do not support further clinical studies in relapsed/refractory AML paediatric patients.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
17
Ages
1 Month to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 121 studies testing decitabine in Leukemia, Myeloid, Acute — 20 open to participants now, 33 under way, 2 of them phase 3. Decitabine · Leukemia, Myeloid, Acute.

Enrollment
87th of 120
17 · median 32
Started
2013
with 8 others
Phase 1/2
15 of 121
2 open now
Registered
46th of 121
by date

Among the 121 studies testing decitabine in Leukemia, Myeloid, Acute, this one is the 87th largest by enrollment of the 120 interventional ones that give a count, is one of 9 that started in 2013, is one of 15 in phase 1/2, and was the 46th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

20 of the 121 studies testing decitabine in Leukemia, Myeloid, Acute are open now, in 5 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About decitabine

Decitabine: first FDA approval 2006 (DACOGEN), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 1 Month to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 121 studies testing decitabine in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

The purpose of this study is to examine the safety and efficacy of decitabine in sequential administration with cytarabine in children with relapsed or refractory acute myeloid leukemia (AML).

Read the detailed description

This is an open-label (identity of assigned study drug will be known) study to evaluate safety, efficacy, and pharmacokinetics (study of what the body does to a drug) of decitabine in sequential administration with cytarabine in children with relapsed or refractory AML. The study will determine the maximum tolerated dose of cytarabine that can be given following decitabine (Phase 1) and the response rate to this combination (Phase 2). Participants may enter a continuation phase of single agent-decitabine infusions for as long as such treatment would be considered beneficial. Serial pharmacokinetic samples will be collected and safety and efficacy will be monitored throughout the study.

03

Conditions studied

  • Acute Myeloid Leukemia

Keywords

  • Acute myeloid leukemia
  • Relapsed or refractory acute myeloid leukemia
  • Children
  • Decitabine
  • DACOGEN
  • Cytarabine
04

Who can participate

Ages eligible
1 Month to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological diagnosis of acute myeloid leukemia (AML) according to the World Health Organization (WHO) classification
  • Diagnosis of AML which has or is refractory to standard of care and no curative therapy exists
  • or Lansky score of at least 50
  • Must be recovered from acute toxicity of any prior treatment
  • Must have adequate organ function according to protocol-defined criteria
  • Agrees to protocol-defined use of effective
  • Female participants of must have a negative serum or urine pregnancy test at Day 1 of Cycle 1

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with decitabine or azacitidine
  • Acute promyelocytic leukemia (M3 subtype in the French-American-British [FAB] classification system)
  • CNS3 disease
  • acute myeloid leukemia (AML) associated with congenital syndromes such as Down syndrome, Fanconi anemia, Bloom syndrome, Kostmann syndrome or Diamond-Blackfan anemia, or bone marrow failure associated with inherited syndromes
  • White blood cell count greater than 40x10\^9 cells/liter(L)
  • Known allergies, , or intolerance to decitabine or cytarabine or their
  • to the use of cytarabine per local prescribing information or prior adverse reactions to cytarabine which would prevent further use
  • Currently enrolled in the treatment phase of an interventional study
  • Female who is pregnant, or breast-feeding, or planning to become pregnant while enrolled in this study or within 3 months after the last dose of study drug (however, the period after which it becomes safe to become pregnant after the last dose of treatment is not known)
  • Male who plans to father a child while enrolled in this study or within 3 months after the last dose of study drug
  • Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the patient or that could prevent, limit, or confound the protocol-specified assessments
  • Any social or medical condition that in the investigator's opinion renders the participant unfit for study participation
  • History of surface antigen (HBsAg) or antibody (anti-HCV) positive, or other clinically active liver disease
  • History of (HIV) antibody positive
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Decitabine and cytarabine

    Drug: Phase1 and Phase 2: decitabine · Drug: Phase 1: cytarabine · Drug: Phase 2: cytarabine

Interventions

  • DrugPhase1 and Phase 2: decitabine

    Drug page: Decitabine

    20 mg/m2 administered by intravenous infusion over 1 hour once daily for 5 consecutive days (Day 1 to Day 5 of 28-day cycle)

  • 1 g/m2, 2 g/m2, and 1.5 g/m2 dose levels administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of 28-day cycle) for the determination of the maximum tolerated dose

  • Phase 1 maximum tolerated dose administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of 28-day cycle)

06

What researchers measure

Primary outcomes

  1. Phase 1: Maximum Tolerated Dose (MTD) of Cytarabine

    The maximum tolerated dose (MTD) for cytarabine was based on the number of participants experiencing a dose-limiting toxicity (DLT) by the end of Cycle 1. A non-hematological DLT was defined as: any Grade \>=3 toxicity that persists for greater than (\>) 5 days or any Grade 2 toxicity that persists for \>7 days and that is intolerable to the participant. A hematological DLT was defined as Grade 4 neutropenia or thrombocytopenia due to a hypoplastic bone marrow at Day 42, in the absence of malignant infiltration. The nominal duration of each cycle was 28 days. However, participants who had not experienced bone marrow recovery at Day 28 were followed up to Day 42. Failure of marrow recovery (improvement to Grade 3) by Day 42 was considered a DLT. The maximum duration of Cycle 1 was therefore 42 days.

    Time frame: Cycle 1 (42 days)

  2. Phase 1 and 2: Total Clearance of Decitabine

    Total clearance of drug after intravenously administration was calculated as: dose/area under the plasma concentration-time curve.

    Time frame: Cycle 1 (28 days) Day 5: pre-infusion, 0.5 hour during infusion, end of infusion and at 5 minute (min), 0.5 hour, 1 hour, and 2 hour after end of infusion

  3. Phase 1 and 2: Volume of Distribution at Steady-State (Vss) of Decitabine

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.

    Time frame: Cycle 1 (28 days) Day 5: pre-infusion, 0.5 hour during infusion, end of infusion and at 5 min, 0.5 hour, 1 hour, and 2 hour after end of infusion

  4. Phase 2: Percentage of Participants Who Achieved CR or CRi at Cycle 1 Day 28

    Response rate (percentage of participants who achieved CR or CRi) was measured using international working group (IWG) criteria. Response rate is defined as complete remission (CR) or complete remission with incomplete blood count recovery (CRi) in children with relapsed or refractory acute myeloid leukemia. CRi is defined as morphologic CR with residual neutropenia (less than \[\<\] 1,000/microliter) or thrombocytopenia \<100,000/ microliter). CR is defined as morphologic leukemia-free state, with less than 5 percentage (%) blasts in aspirate sample with marrow spicules and with a count of greater than or equal to (\>=) 200 nucleated cells, plus absolute neutrophil count (ANC) greater than (\>) 1,000/ microliter, platelet count of \>100,000/microliter and participant must be independent of transfusions for a minimum of 1 week before each marrow assessment.

    Time frame: Cycle 1 (28 days) Day 28

  5. Phase 2: Percentage of Participants Who Achieved CR or CRi at Cycle 2 Day 28

    Response rate (percentage of participants who achieved CR or CRi) was measured using international working group (IWG) criteria. Response rate is defined as complete remission (CR) or complete remission with incomplete blood count recovery (CRi) in children with relapsed or refractory acute myeloid leukemia. CRi is defined as morphologic CR with residual neutropenia (less than \[\<\] 1,000/microliter) or thrombocytopenia \<100,000/ microliter). CR is defined as morphologic leukemia-free state, with less than 5 percentage (%) blasts in aspirate sample with marrow spicules and with a count of greater than or equal to (\>=) 200 nucleated cells, plus absolute neutrophil count (ANC) greater than (\>) 1,000/ microliter, platelet count of \>100,000/microliter and participant must be independent of transfusions for a minimum of 1 week before each marrow assessment.

    Time frame: Cycle 2 (28 days) Day 28

  6. Phase 2: Percentage of Participants Who Achieved CR or CRi at End of Study Treatment

    Response rate (percentage of participants who achieved CR or CRi) was measured using international working group (IWG) criteria. Response rate is defined as complete remission (CR) or complete remission with incomplete blood count recovery (CRi) in children with relapsed or refractory acute myeloid leukemia. CRi is defined as morphologic CR with residual neutropenia (less than \[\<\] 1,000/microliter) or thrombocytopenia \<100,000/ microliter). CR is defined as morphologic leukemia-free state, with less than 5 percentage (%) blasts in aspirate sample with marrow spicules and with a count of greater than or equal to (\>=) 200 nucleated cells, plus absolute neutrophil count (ANC) greater than (\>) 1,000/ microliter, platelet count of \>100,000/microliter and participant must be independent of transfusions for a minimum of 1 week before each marrow assessment.

    Time frame: End of study treatment (approximately 3 years)

Secondary outcomes

  1. Phase 1 and 2: Maximum Plasma Concentration (Cmax) of Decitabine

    Cmax is the maximum observed plasma concentration of Decitabine.

    Time frame: Cycle 1 (28 days) Day 5: pre-infusion, 0.5 hour during infusion, end of infusion and at 5 min, 0.5 hour, 1 hour, and 2 hour after end of infusion

  2. Phase 1 and 2: Area Under the Plasma Concentration-Time Curve (AUC) of Decitabine

    AUC is the area under the plasma concentration-time curve of decitabine.

    Time frame: Cycle 1 (28 days) Day 5: pre-infusion, 0.5 hour during infusion, end of infusion and at 5 min, 0.5 hour, 1 hour, and 2 hour after end of infusion

  3. Phase 2: Duration of Response

    Duration of response is defined as weeks from date of first response to date of first relapse or date of death.

    Time frame: From time of response to relapse, study completion/withdrawal, or death, whichever comes first, for up to approximately 3 years 10 months

  4. Phase 2: Overall Response Rate

    Overall response rate is defined as percentage of participants with complete remission (CR) +complete remission with incomplete blood count recovery (CRi)+partial remission (PR) per IWG Criteria. CRi: morphologic CR with residual neutropenia (less than \[\<\] 1,000/microliter) or thrombocytopenia \<100,000/microliter). CR is defined as morphologic leukemia-free state, with less than 5 percentage (%) blasts in aspirate sample with marrow spicules and with a count of greater than or equal to (\>=) 200 nucleated cells, plus absolute neutrophil count (ANC) greater than (\>) 1,000/ microliter platelet count of \>100,000/microliter and participant must be independent of transfusions for a minimum of 1 week before each marrow assessment. PR: all the same hematologic values of a CR, but with a decrease of \>=50% of the percentage of blasts to 5% to 25% in the bone marrow aspirate.

    Time frame: Up to approximately 3 years 10 months

  5. Phase 1 and 2: Overall Survival (OS)

    OS is defined as the time from the date of first dose of study drug to date of death from any cause. If the participant is alive or the vital status is unknown, the participant will be censored at the date the participant will be last known to be alive.

    Time frame: From enrollment to death or withdrawal, whichever comes first, for up to approximately 3 years 10 months

  6. Phase 1 and 2: Event-Free Survival

    Event free survival is defined as the time from first dose of study drug to relapse from CR, death, or second malignancy for participants who achieved CR. CR is defined as morphologic leukemia-free state, with less than 5 percentage (%) blasts in aspirate sample with marrow spicules and with a count of greater than or equal to (\>=) 200 nucleated cells, plus absolute neutrophil count (ANC) greater than (\>) 1,000/ microliter platelet count of \>100,000/microliter and participant must be independent of transfusions for a minimum of 1 week before each marrow assessment.

    Time frame: From enrollment to progression/relapse, death, or withdrawal, whichever comes first, for up to approximately 3 years 10 months

  7. Phase 1 and 2: Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs)

    TEAEs are defined as adverse events with onset or worsening on or after date of first dose of study treatment. An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.

    Time frame: Approximately 3 years 10 months

07

Results

Posted Jun 17, 2019
Limitations and caveats
The Sponsor terminated the study earlier than planned due to lack of efficacy with 8 evaluable participants in Phase 2 with no clinically meaningful anti-leukemic activity.

Participant flow

Phase 1
Participant flow — Phase 1
MilestoneCohort 1: Decitabine 20 mg/m^2 + Cytarabine 1 g/m^2Cohort 2: Decitabine 20 mg/m^2 + Cytarabine 2 g/m^2
Started97
Completed07
Not completed90
Withdrew: Lack of efficacy80
Withdrew: Other10
Phase 2
Participant flow — Phase 2
MilestoneCohort 1: Decitabine 20 mg/m^2 + Cytarabine 1 g/m^2Cohort 2: Decitabine 20 mg/m^2 + Cytarabine 2 g/m^2
Started08
Completed00
Not completed08
Withdrew: Physician decision01
Withdrew: Proceed to transplant03
Withdrew: Lack of efficacy04

Outcome measures

PrimaryPhase 1: Maximum Tolerated Dose (MTD) of Cytarabine

The maximum tolerated dose (MTD) for cytarabine was based on the number of participants experiencing a dose-limiting toxicity (DLT) by the end of Cycle 1. A non-hematological DLT was defined as: any Grade \>=3 toxicity that persists for greater than (\>) 5 days or any Grade 2 toxicity that persists for \>7 days and that is intolerable to the participant. A hematological DLT was defined as Grade 4 neutropenia or thrombocytopenia due to a hypoplastic bone marrow at Day 42, in the absence of malignant infiltration. The nominal duration of each cycle was 28 days. However, participants who had not experienced bone marrow recovery at Day 28 were followed up to Day 42. Failure of marrow recovery (improvement to Grade 3) by Day 42 was considered a DLT. The maximum duration of Cycle 1 was therefore 42 days.

Time frame:
Cycle 1 (42 days)
Reported as:
Number · gram per square meter
Phase 1: Maximum Tolerated Dose (MTD) of Cytarabine
gram per square meterDecitabine (Dacogen) + Cytarabine
Phase 1: Maximum Tolerated Dose (MTD) of Cytarabine2
SecondaryPhase 1 and 2: Maximum Plasma Concentration (Cmax) of Decitabine

Cmax is the maximum observed plasma concentration of Decitabine.

Time frame:
Cycle 1 (28 days) Day 5: pre-infusion, 0.5 hour during infusion, end of infusion and at 5 min, 0.5 hour, 1 hour, and 2 hour after end of infusion
Reported as:
Median · nanogram per milliliter (ng/mL)
Phase 1 and 2: Maximum Plasma Concentration (Cmax) of Decitabine
nanogram per milliliter (ng/mL)Decitabine (Dacogen) + Cytarabine
> 1 month to <= 2 years118.4 (17.6 to 1621)
> 2 to <= 6 years123.1 (15.6 to 1012)
> 6 to <= 12 years148.7 (16.5 to 1415)
> 12 to <= 16 years151.4 (19.1 to 1303)
PrimaryPhase 1 and 2: Total Clearance of Decitabine

Total clearance of drug after intravenously administration was calculated as: dose/area under the plasma concentration-time curve.

Time frame:
Cycle 1 (28 days) Day 5: pre-infusion, 0.5 hour during infusion, end of infusion and at 5 minute (min), 0.5 hour, 1 hour, and 2 hour after end of infusion
Reported as:
Median · liter per hour per square meter
Phase 1 and 2: Total Clearance of Decitabine
liter per hour per square meterDecitabine (Dacogen) + Cytarabine
>1 month to less than or equal to (<=) 2 years160.6 (11.7 to 942.3)
Greater than (>) 2 to <= 6 years152.1 (19.5 to 1061)
> 6 to <= 12 years125.9 (13.3 to 951.3)
> 12 to <= 16 years123.2 (11.4 to 832.6)
SecondaryPhase 1 and 2: Area Under the Plasma Concentration-Time Curve (AUC) of Decitabine

AUC is the area under the plasma concentration-time curve of decitabine.

Time frame:
Cycle 1 (28 days) Day 5: pre-infusion, 0.5 hour during infusion, end of infusion and at 5 min, 0.5 hour, 1 hour, and 2 hour after end of infusion
Reported as:
Median · nanogram*hour per milliliter (ng*h/mL)
Phase 1 and 2: Area Under the Plasma Concentration-Time Curve (AUC) of Decitabine
nanogram*hour per milliliter (ng*h/mL)Decitabine (Dacogen) + Cytarabine
> 1 month to <= 2 years124.8 (21.3 to 1708)
> 2 to <= 6 years131.5 (19.3 to 1028)
> 6 to <= 12 years158.9 (21.0 to 1508)
> 12 to <= 16 years162.4 (24.2 to 1747)
SecondaryPhase 2: Duration of Response

Duration of response is defined as weeks from date of first response to date of first relapse or date of death.

Time frame:
From time of response to relapse, study completion/withdrawal, or death, whichever comes first, for up to approximately 3 years 10 months
Reported as:
Number · weeks
Phase 2: Duration of Response
weeksDecitabine (Dacogen) + Cytarabine
Participant 144.6
Participant 26.3
SecondaryPhase 2: Overall Response Rate

Overall response rate is defined as percentage of participants with complete remission (CR) +complete remission with incomplete blood count recovery (CRi)+partial remission (PR) per IWG Criteria. CRi: morphologic CR with residual neutropenia (less than \[\<\] 1,000/microliter) or thrombocytopenia \<100,000/microliter). CR is defined as morphologic leukemia-free state, with less than 5 percentage (%) blasts in aspirate sample with marrow spicules and with a count of greater than or equal to (\>=) 200 nucleated cells, plus absolute neutrophil count (ANC) greater than (\>) 1,000/ microliter platelet count of \>100,000/microliter and participant must be independent of transfusions for a minimum of 1 week before each marrow assessment. PR: all the same hematologic values of a CR, but with a decrease of \>=50% of the percentage of blasts to 5% to 25% in the bone marrow aspirate.

Time frame:
Up to approximately 3 years 10 months
Reported as:
Number · Percentage of participants
Phase 2: Overall Response Rate
Percentage of participantsDecitabine (Dacogen) + Cytarabine
Phase 2: Overall Response Rate37.5
SecondaryPhase 1 and 2: Overall Survival (OS)

OS is defined as the time from the date of first dose of study drug to date of death from any cause. If the participant is alive or the vital status is unknown, the participant will be censored at the date the participant will be last known to be alive.

Time frame:
From enrollment to death or withdrawal, whichever comes first, for up to approximately 3 years 10 months
Reported as:
Median · months
Phase 1 and 2: Overall Survival (OS)
monthsDecitabine (Dacogen) + Cytarabine
Phase 1 and 2: Overall Survival (OS)5.1 (3.1 to 11.4)
SecondaryPhase 1 and 2: Event-Free Survival

Event free survival is defined as the time from first dose of study drug to relapse from CR, death, or second malignancy for participants who achieved CR. CR is defined as morphologic leukemia-free state, with less than 5 percentage (%) blasts in aspirate sample with marrow spicules and with a count of greater than or equal to (\>=) 200 nucleated cells, plus absolute neutrophil count (ANC) greater than (\>) 1,000/ microliter platelet count of \>100,000/microliter and participant must be independent of transfusions for a minimum of 1 week before each marrow assessment.

Time frame:
From enrollment to progression/relapse, death, or withdrawal, whichever comes first, for up to approximately 3 years 10 months
Reported as:
Median · days
Phase 1 and 2: Event-Free Survival
daysDecitabine (Dacogen) + Cytarabine
Phase 1 and 2: Event-Free Survival1 (1 to 348)
SecondaryPhase 1 and 2: Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs)

TEAEs are defined as adverse events with onset or worsening on or after date of first dose of study treatment. An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.

Time frame:
Approximately 3 years 10 months
Reported as:
Count of participants · Participants
Phase 1 and 2: Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs)
ParticipantsDecitabine (Dacogen) + Cytarabine
Phase 1 and 2: Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs)17
PrimaryPhase 1 and 2: Volume of Distribution at Steady-State (Vss) of Decitabine

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.

Time frame:
Cycle 1 (28 days) Day 5: pre-infusion, 0.5 hour during infusion, end of infusion and at 5 min, 0.5 hour, 1 hour, and 2 hour after end of infusion
Reported as:
Median · liter per square meter
Phase 1 and 2: Volume of Distribution at Steady-State (Vss) of Decitabine
liter per square meterDecitabine (Dacogen) + Cytarabine
> 1 month to <= 2 years35.9 (2.7 to 558.4)
> 2 to <= 6 years36.5 (1.4 to 535.0)
> 6 to <= 12 years31.8 (2.0 to 645.8)
> 12 to <= 16 years35.9 (2.8 to 578.9)
PrimaryPhase 2: Percentage of Participants Who Achieved CR or CRi at Cycle 1 Day 28

Response rate (percentage of participants who achieved CR or CRi) was measured using international working group (IWG) criteria. Response rate is defined as complete remission (CR) or complete remission with incomplete blood count recovery (CRi) in children with relapsed or refractory acute myeloid leukemia. CRi is defined as morphologic CR with residual neutropenia (less than \[\<\] 1,000/microliter) or thrombocytopenia \<100,000/ microliter). CR is defined as morphologic leukemia-free state, with less than 5 percentage (%) blasts in aspirate sample with marrow spicules and with a count of greater than or equal to (\>=) 200 nucleated cells, plus absolute neutrophil count (ANC) greater than (\>) 1,000/ microliter, platelet count of \>100,000/microliter and participant must be independent of transfusions for a minimum of 1 week before each marrow assessment.

Time frame:
Cycle 1 (28 days) Day 28
Reported as:
Number · percentage of participants
Phase 2: Percentage of Participants Who Achieved CR or CRi at Cycle 1 Day 28
percentage of participantsDecitabine (Dacogen) + Cytarabine
Phase 2: Percentage of Participants Who Achieved CR or CRi at Cycle 1 Day 2820
PrimaryPhase 2: Percentage of Participants Who Achieved CR or CRi at Cycle 2 Day 28

Response rate (percentage of participants who achieved CR or CRi) was measured using international working group (IWG) criteria. Response rate is defined as complete remission (CR) or complete remission with incomplete blood count recovery (CRi) in children with relapsed or refractory acute myeloid leukemia. CRi is defined as morphologic CR with residual neutropenia (less than \[\<\] 1,000/microliter) or thrombocytopenia \<100,000/ microliter). CR is defined as morphologic leukemia-free state, with less than 5 percentage (%) blasts in aspirate sample with marrow spicules and with a count of greater than or equal to (\>=) 200 nucleated cells, plus absolute neutrophil count (ANC) greater than (\>) 1,000/ microliter, platelet count of \>100,000/microliter and participant must be independent of transfusions for a minimum of 1 week before each marrow assessment.

Time frame:
Cycle 2 (28 days) Day 28
Reported as:
Number · percentage of participants
Phase 2: Percentage of Participants Who Achieved CR or CRi at Cycle 2 Day 28
percentage of participantsDecitabine (Dacogen) + Cytarabine
Phase 2: Percentage of Participants Who Achieved CR or CRi at Cycle 2 Day 2866.7
PrimaryPhase 2: Percentage of Participants Who Achieved CR or CRi at End of Study Treatment

Response rate (percentage of participants who achieved CR or CRi) was measured using international working group (IWG) criteria. Response rate is defined as complete remission (CR) or complete remission with incomplete blood count recovery (CRi) in children with relapsed or refractory acute myeloid leukemia. CRi is defined as morphologic CR with residual neutropenia (less than \[\<\] 1,000/microliter) or thrombocytopenia \<100,000/ microliter). CR is defined as morphologic leukemia-free state, with less than 5 percentage (%) blasts in aspirate sample with marrow spicules and with a count of greater than or equal to (\>=) 200 nucleated cells, plus absolute neutrophil count (ANC) greater than (\>) 1,000/ microliter, platelet count of \>100,000/microliter and participant must be independent of transfusions for a minimum of 1 week before each marrow assessment.

Time frame:
End of study treatment (approximately 3 years)
Reported as:
Number · percentage of participants
Phase 2: Percentage of Participants Who Achieved CR or CRi at End of Study Treatment
percentage of participantsDecitabine (Dacogen) + Cytarabine
Phase 2: Percentage of Participants Who Achieved CR or CRi at End of Study Treatment12.5

Adverse events

Collected over Screening up to end of study (approximately 3 years 10 months). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1 (Cohort 1): Dacogen + Cytarabine8/9 (88.9%)4/9 (44.4%)9/9 (100%)
Phase 1 (Cohort 2) and Phase 2: Dacogen + Cytarabine6/8 (75%)4/8 (50%)8/8 (100%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventPhase 1 (Cohort 1): Dacogen + CytarabinePhase 1 (Cohort 2) and Phase 2: Dacogen + Cytarabine
Febrile NeutropeniaBlood and lymphatic system disorders3/92/8
SepsisInfections and infestations0/92/8
AnaemiaBlood and lymphatic system disorders0/91/8
NeutropeniaBlood and lymphatic system disorders0/91/8
ThrombocytopeniaBlood and lymphatic system disorders0/91/8
KeratitisEye disorders0/91/8
PyrexiaGeneral disorders1/91/8
Lung InfectionInfections and infestations0/91/8
Complication Associated with DeviceGeneral disorders1/90/8
Skin ExfoliationSkin and subcutaneous tissue disorders1/90/8
Most frequent other events
Showing 10 of 93
Most frequent other events
EventPhase 1 (Cohort 1): Dacogen + CytarabinePhase 1 (Cohort 2) and Phase 2: Dacogen + Cytarabine
AnaemiaBlood and lymphatic system disorders6/98/8
PyrexiaGeneral disorders2/96/8
ThrombocytopeniaBlood and lymphatic system disorders6/94/8
LeukopeniaBlood and lymphatic system disorders1/95/8
VomitingGastrointestinal disorders4/95/8
Febrile NeutropeniaBlood and lymphatic system disorders5/90/8
NeutropeniaBlood and lymphatic system disorders2/94/8
StomatitisGastrointestinal disorders1/93/8
HypokalaemiaMetabolism and nutrition disorders3/93/8
DiarrhoeaGastrointestinal disorders3/92/8

Baseline characteristics

Population included all enrolled participants in Phase 1 and Phase 2.

Age, Continuous
Age, Continuous(months)Dacogen + Cytarabine
Mean73.3 ± 46.26
Sex: Female, Male
Sex: Female, Male(Participants)Dacogen + Cytarabine
Female4
Male13
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dacogen + Cytarabine
Hispanic or Latino2
Not Hispanic or Latino10
Unknown or Not Reported5
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dacogen + Cytarabine
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American2
White8
More than one race1
Unknown or Not Reported5
Region of Enrollment
Region of Enrollment(Participants)Dacogen + Cytarabine
Belgium1
Denmark2
France4
Germany1
Netherlands1
Spain4
United Kingdom4
08

Study locations

17 sites
  • Gent, Belgium
  • Copenhagen Ø, Denmark
  • Paris, France
  • Toulouse Cedex 9, France
  • Vandoeuvre-Lès-Nancy, France
  • Essen, Germany
  • Hamburg, Germany
  • Hannover, Germany
  • Stuttgart, Germany
  • Rotterdam, Netherlands
  • Barcelona, Spain
  • Madrid, Spain
  • Valencia, Spain
  • Birmingham, United Kingdom
  • Cambridge, United Kingdom
  • Glasgow, United Kingdom
  • Sutton, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2013 to primary completion in Aug 2017, 46 months.

Results were first posted in Jun 2019, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2013
First posted
May 14, 2013
StartActual
Oct 22, 2013
Primary completionActual
Aug 28, 2017
CompletionActual
Aug 28, 2017
Results first posted
Jun 17, 2019
Last update
Jun 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01853228
Responsible party
Sponsor
First posted
May 14, 2013
Start date
Oct 22, 2013
Primary completion
Aug 28, 2017
Completion
Aug 28, 2017
Results posted
Jun 17, 2019
Last update
Jun 17, 2019

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Decitabine

Start the discussion